1188425-47-9

Basic information

• Product Name: N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide
• Synonyms: N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide
• CAS NO: 1188425-47-9
• Molecular Weight: 489.479
• Mol File: 1188425-47-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide(CAS DataBase Reference)
• NIST Chemistry Reference: N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide(1188425-47-9)
• EPA Substance Registry System: N'-(2-((3,4-difluorobenzyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide(1188425-47-9)

Safety Data

• Hazardous Substances Data: 1188425-47-9(Hazardous Substances Data)

Upstream product

• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 32833-96-8 N,N-dimethyloxamic acid 
• 1188429-06-2 ethyl 10-(((benzyloxy)carbonyl)amino)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a] azepine-2-carboxylate 
• 72235-53-1 3,4-difluorobenzylamine 
• 1188429-05-1 benzyl 4-(chloromethyl)-1-cyanocyclohexylcarbamate 
• 1188429-04-0 8-(chloromethyl)-1,4-dioxaspiro[4.5]decane 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 

Relevant articles and documents

Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors

The design, synthesis and structure-activity relationships associated with a series of bridged tricyclic pyrimidinone carboxamides as potent inhibitors of HIV-1 integrase strand transfer are described. Structural modifications to these molecules were made in order to examine the effect on potency towards wild-type and clinically-relevant resistant viruses. The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.